Overview of the BOSTON Trial Evaluating a Selinexor Triplet Regimen

Opinion
Video

Noa Biran, MD, discusses how the phase III BOSTON trial evaluates selinexor + bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed/refractory myeloma.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
2 experts in this video
2 experts in this video
2 experts are featured in this series.
2 experts are featured in this series.
4 experts in this video
2 experts in this video
Related Content
Noa Biran, MD, speaks about recently approved bispecific therapies and current trials that may impact the standard of care in relapsed/refractory multiple myeloma.

Optimizing Novel Treatment Options in Relapsed/Refractory Multiple Myeloma

Russ Conroy
March 4th 2024
Article

Noa Biran, MD, speaks about recently approved bispecific therapies and current trials that may impact the standard of care in relapsed/refractory multiple myeloma.